mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the causative infection of a global pandemic that has led to more than 2 million deaths worldwide. The Moderna mRNA-1273 vaccine has demonstrated ~94% efficacy in a Phase 3 study and has been approved under Emergency Use Authorization....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:bioRxiv
Egile Nagusiak: Wu, Kai, Werner, Anne P., Moliva, Juan I., Koch, Matthew, Choi, Angela, Stewart-Jones, Guillaume B.E., Bennett, Hamilton, Boyoglu-Barnum, Seyhan, Shi, Wei, Graham, Barney S, Carfi, Andrea, Corbett, Kizzmekia S., Seder, Robert A., Edwards, Darin K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Cold Spring Harbor Laboratory 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7836112/
https://ncbi.nlm.nih.gov/pubmed/33501442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.01.25.427948
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak